Accessibility Menu
Crinetics Pharmaceuticals logo

Crinetics Pharmaceuticals

(NASDAQ) CRNX

Current Price$36.08
Market Cap$3.79B
Since IPO (2018)+47%
5 Year+76%
1 Year+20%
1 Month-2%

Crinetics Pharmaceuticals Financials at a Glance

Market Cap

$3.79B

Revenue (TTM)

$18.07M

Net Income (TTM)

-$496.39M

EPS (TTM)

-$5.13

P/E Ratio

-7.00

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$36.08

Volume

50,435

Open

$36.93

Previous Close

$36.08

Daily Range

$36.01 - $37.51

52-Week Range

$25.83 - $57.99

Estimated Earnings Date

Aug 6, 2026

CRNX: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Crinetics Pharmaceuticals

Industry

Pharmaceuticals

Employees

594

CEO

Scott R. Struthers, PhD

Headquarters

San Diego, CA 92121, US

CRNX Financials

Key Financial Metrics (TTM)

Gross Margin

98.89%

Operating Margin

-3020.32%

Net Income Margin

-2747.18%

Return on Equity

-43.96%

Return on Capital

-49.66%

Return on Assets

-35.42%

Earnings Yield

-14.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.79B

Shares Outstanding

105.44M

Volume

50.44K

Avg. Volume

1.16M

Financials (TTM)

Gross Profit

$17.87M

Operating Income

-$545.74M

EBITDA

-$492.08M

Operating Cash Flow

-$414.17M

Capital Expenditure

-$5.34M

Free Cash Flow

-$419.52M

Cash & ST Invst.

$1.29B

Total Debt

$47.86M

Crinetics Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$10.73M

+2873.4%

Gross Profit

$10.53M

+2818.0%

Gross Margin

98.14%

N/A

Market Cap

$3.79B

N/A

Market Cap/Employee

$8.66M

N/A

Employees

437

N/A

Net Income

-$127.85M

-32.1%

EBITDA

-$126.69M

-32.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.29B

+1.3%

Total Debt

$47.86M

-5.8%

Accounts Receivable

$5.68M

-22.3%

Inventory

$3.06M

N/A

Long Term Debt

$41.32M

-6.0%

Short Term Debt

$6.54M

-5.0%

Return on Assets

-35.42%

N/A

Return on Invested Capital

-41.03%

N/A

Free Cash Flow

-$125.52M

-40.0%

Operating Cash Flow

-$124.70M

-41.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NAMSNewAmsterdam Pharma Company N.V.
$32.63+3.92%
ACADACADIA Pharmaceuticals Inc.
$23.36+3.36%
DYNDyne Therapeutics, Inc.
$20.33+0.35%
XENEXenon Pharmaceuticals Inc.
$55.58+1.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$7.86+0.26%
SOFISoFi Technologies
$17.31+0.00%
IBITiShares Bitcoin Trust
$33.87-0.04%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.27+0.01%

Questions About CRNX

What is the current price of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals is trading at $36.08 per share.

What is the 52-week range for Crinetics Pharmaceuticals?

Over the past 52 weeks, Crinetics Pharmaceuticals has traded between $25.83 and $57.99.

How much debt does Crinetics Pharmaceuticals have?

As of the most recent reporting period, Crinetics Pharmaceuticals reported total debt of $47.86M.

How much cash does Crinetics Pharmaceuticals have on hand?

Crinetics Pharmaceuticals reported $114.34M in cash and cash equivalents in its most recent financial results.

What is Crinetics Pharmaceuticals’s dividend yield?

Crinetics Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.